Dr. John H. Tu, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 130
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NY license 220699
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Rochester General Hospital Rochester, NY
Medical groups
- Dermatology Associates of Rochester, PC (12 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 130
- Services billed
- 379
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 104 | 79 |
| Destruction of precancer skin growth, 2-14 growths | 81 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 31 | 27 |
| New patient office or other outpatient visit, 30-44 minutes | 31 | 31 |
| Biopsy of related skin growth, first growth | 29 | 24 |
| Established patient office or other outpatient visit, 10-19 minutes | 26 | 24 |
| Destruction of precancer skin growth, 1 growth | 22 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $541,350 in research payments for these studies, mostly to the institutions running them.
- 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-lab…
Novartis Pharmaceuticals Corporation - A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
UCB SA · Active, not recruiting · NCT06506916 - The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Incyte Corporation - Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Sanofi US Services Inc. · Active, not recruiting · NCT05492578 - Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc. · Completed · NCT05662202 - A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
Sanofi US Services Inc. · Completed · NCT06015308 - A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
E.r. Squibb & Sons, L.l.c. · Completed · NCT05701995 - Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
Biofrontera Inc. · Completed · NCT05080764 - A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation - An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS)
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.